SavedAdd your journal

Journals / Mustafa Kemal Üniversitesi Tıp Dergisi / 2010 / Cilt: 1 - Sayı: 1

AT-III LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN PATIENTS IN PEDIATRIC INTENSIVE CARE UNIT

YOĞUN BAKIMA YATAN HASTALARDA ATIII SEVİYESİ VE PROGNOSTİK DEĞERİ

Bedir Ay
Murat Tutanç
Servet Yel
Metin Kaplan
Mehmet Boşnak
Emre Ayıntap
Pages
1–5
Publication Date
2015-03-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Particular activity tobelow 50% is considered a powerful prognostic indicator.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Our objective is to investigate the prognostic value of Antithrombin III in our intensive care.Gereç ve yöntem: 215 patients admitted to intensive care were included.
📊
Key Findings & Data:The age of patients were between 1-16 years, 125 weremale, and 90 female.Results: Prognosis is related to the decrease in antithrombin III activity.Conclusion: Our study showed that the decrease in antithrombin III activity is closely related to prognosis.
💡
Conclusion & Impact:Particular activity tobelow 50% is considered a powerful prognostic indicator.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Çocuk yo un bakım · Antitrombin III seviyesi · prognostik de er

Abstract

Aim: Our objective is to investigate the prognostic value of Antithrombin III in our intensive care.Gereç ve yöntem: 215 patients admitted to intensive care were included. The age of patients were between 1-16 years, 125 weremale, and 90 female.Results: Prognosis is related to the decrease in antithrombin III activity.Conclusion: Our study showed that the decrease in antithrombin III activity is closely related to prognosis. Particular activity tobelow 50% is considered a powerful prognostic indicator.

Özet

Amaç: Antitrombin 3’ün yo÷un bakıma yatan hastalardaki prognostik de÷erini araútırmak.Gereç ve yöntem: Çalıúmamızda yo÷un bakıma yatan 215 hasta dahil edildi. Hastalar 1-16 yaú arasındaydı, 90’ı kız 125’i erkekti.Bulgular: Antitrombin III aktivitesindeki azalma prognozla yakın iliúkili görülmektedir.Sonuç: Bizim çalıúmamızda vardı÷ımız sonuç gibi Antitrombin III aktivitesindeki azalma prognozla yakın iliúkili görülmektedir.Özellikle aktivitenin %50 nin altına inmesi güçlü bir prognostik gösterge olarak kabul edilmektedir.

🔖

Cite This Article

Ay, B., Tutanç, M., Yel, S., Kaplan, M., Boşnak, M., Ayıntap, E. (2015). AT-III LEVEL AND ITS PROGNOSTIC SIGNIFICANCE IN PATIENTS IN PEDIATRIC INTENSIVE CARE UNIT. Mustafa Kemal Üniversitesi Tıp Dergisi, Cilt: 1 - Sayı: 1, 1–5. https://ajindex.com/articles/693034

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Schnitzel H, Weilemann L S. Antithrombin substitution therapy. Blood Coag Fibrinol 1998; 9 (suppl 3): 17-22.
  2. Pratt CW, Church FC. Antithrombin structure and function. Semin Hematol 1991; 28: 3-9. Van’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin III and heparin cofactor II. J Biol Chem 1997; 14: 4367-4377.
  3. Pizzo SV, Durham Ph D. Serpin receptor 1: hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med; 87 (suppl 3B): 10-14. Mammen EF. Antithrombin:Its physiological importance and role in D Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 1998; 24(1):71-80. Nielsen JD. The effect of antithrombin on systemic inflammatory response in disseminated intravascular coagulation. Blood Coag Fibrinol 1998; (suppl 3): 11-15.
  4. Davie E, Ratnoff O D. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1312. Vinazzer H. Clinical use’s of ATIII. Von Sang 1987; 53: 193-198. Mamnen EF. Antithrombin: Its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24: 19-25.
  5. Tahtacı N, Elmacıo Niessen RWL, Lamping RJ, Jonsen PM, et. al. Antithrombin acts as a negative acute phase protein as established with studies on Hep G2 cells and in baboons. Thromb Haemost 1997; 78:1088-1092.
  6. Mammen EF, Balk R, Emerson T Jr, et. al. Therapeutic use of antithrombin concentrates in sepsis. Semin Thromb Hemost 1998; 24: 183-194. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24: 61-69.
  7. Warren BL, Eid A, Singer P, et. al. High dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001; 286: 1869-1878.
  8. Olcay L, Gürgey A. Herediter trombotik hastalıklar. Katkı Pediatri Derg 1995; 6:887-907.
  9. Casgriff JM, Bishop DT, Hersfold EJ, Skolnick MH, et. al. Hereditary antithrombin deficiency diagnosis and treatment. Medicine 1983; 62: 4. Wilson C, Walker ID, Davidson JF. Mesenteric venous thrombosis and ATIII deficiency. J Clin Pathol 1987; 40: 906-908. Lee MK. Cerebral Venous Thrombosis with ATIII deficiency. Aust NZ J Med 1991;21. Levi M, Ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975- - Vervloet MG, Thijs LG, Hack CE. Derangement’s of coagulation and fibri